A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3). We conducted a phase Ib study to investigate the safety, tolerability, and efficacy of mivavotinib in patients with refractory...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Keith W. Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W. Burke, Harry Erba, Trisha M. Wise-Draper, Gail J. Roboz, Nikolaos Papadantonakis, Trivikram Rajkhowa, Daniela Hernandez, Iwona Dobler, Richard C. Gregory, Cheryl Li, Shining Wang, Kate Stumpo, Karuppiah Kannan, Harry Miao, Mark Levis
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Ferrata Storti Foundation 2022-10-01
Sarja:	Haematologica
Linkit:	https://haematologica.org/article/view/10829
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!